MK-3475

This page shows the latest MK-3475 news and features for those working in and with pharma, biotech and healthcare.

GSK wins approval for skin cancer drug Mekinist in EU

be taken up by immune checkpoint inhibitors - BMS' nivolumab and Merck &Co's pembrolizumab (MK-3475) - which are currently in late-stage testing.

Latest news

Merck could win anti-PD1 therapy race in Europe

Pembrolizumab (formerly lambrolizumab; MK-3475) is one of the highlights of Merck's R&D pipeline and is being evaluated across more than 30 types of cancer, with peak sales estimated
ASCO: Merck’s anti-PD1 impresses in skin and lung cancer

ASCO: Merck’ s anti-PD1 impresses in skin and lung cancer. Promising MK-3475 immunotherapy to be known as pembrolizumab. ... New data on Merck &Co's recently-filed anti-PD1 drug pembrolizumab (MK-3475) suggest the drug could be a 'paradigm shift' in
AZ starts pivotal trials of lung cancer immunotherapy

Meanwhile, Merck &Co's MK-3475 - filed for melanoma earlier this year - and Bristol-Myers Squibb's nivolumab for NSCLC are targeting a related receptor called PD1.
FDA grants priority review to Merck’s cancer antibody

FDA grants priority review to Merck’ s cancer antibody. Will speed up assessment of MK-3475 in skin cancer melanoma. ... Merck has also signed agreements with rivals Pfizer, Amgen and Incyte to test MK-3475 in combination with other oncology drugs
Novartis enters PD-1 race via CoStim acquisition

Of these Merck appears to be in the lead, as it has filed a rolling marketing submission for its MK-3475. ... therapies seems backed up by Merck's recent announcement of a series of collaborations on MK-3475 with other drugmakers.

More from news
Approximately 7 fully matching, plus 8 partially matching documents found.

Latest Intelligence

Interview: Bruno Strigini, MSD

Here among the products he points to are the company's anti-PD-1 immunotherapy MK-3475, for which a rolling approval was filed earlier this year as a second-line
Pharma deals during February 2014

Merck &Co also signed three separate agreements with Amgen, Incyte and Pfizer to investigate combination regimes with its experimental anti-PD-1 immunotherapy, MK-3475 (see Box 1). ... MK-3475 was awarded FDA breakthrough therapy status for advanced

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

Bruno Strigini leaves Merck & Co for Novartis

Leading the field though is Strigini's former company Merck &Co, which has already filed MK-3475 in the US to treat advanced melanoma.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Digital Senior Account Director – Healthcare Advertising – Londo...: Salary TBC

Engagement Strategist, Healthcare Brand Communications, London, ...: Circa £60K

HOME BASED Senior Account Executive / Account Manager - Medical ...: Salary TBC

Senior Account Manager / Account Director: Great salary and bebefits

Senior Medical Writer: Great salary and benefits

Account Director - Global Healthcare Advertising (Digital) - Lon...: £55000 - £65000

Senior Account Manager – Med Comms – Kent: Salary TBC

Senior Programme Executive: Salary TBC

Editor – Medical Education Agency – Bucks: Salary TBC

Principal Medical Writer, Medical Communications, Relocate to Ca...: Excellent Salary

Editorial Team Leader or Scientific Director: £50, 000 - £55, 000 benefits

Senior Medical Writer: Great salary and bebefits

FREELANCE Account Manager – Creative Healthcare Advertising – Lo...: SUPERB DAY RATES AVAILABLE

Science writer, Healthcare Brand Communications, London, £45-50K...: £45-50K

Editor > Senior Editor – Medical Education – London: Very competitive with excellent benefits

Senior / Principal Regulatory Writer – Home Working - UK or US: HIGHLEY COMPETATIVE SALARY, BONUS &BENEFITS

Account Manager – Med Comms – London: Salary TBC

Editorial Director – Medical Education – Oxford: Negotiable

Head of Operations/ BUD, Healthcare PR, London – Excellent leade...: Excellent Package

Senior Medical Writer, Medical Communications, Relocate to Cardi...: Excellent Salary

Senior Account Manager or AD - Medical Communications: Salary TBC

FREELANCE OPPORTUNITIES!!!!! Medical Education - Healthcare Adve...: EXCELLENT DAY RATES AVAILABLE

Medical Writer - (London, Brighton or Copenhagen): Competitive

Scientific Director: Great salary and bebefits

Account Manager, Healthcare PR: £40, 000 – £42, 000 great benefits and bonuses

Subscribe to our email news alerts

PMHub

Add my company

Six Degrees Medical Consulting

Partnering with top global pharmaceutical companies, we push the boundaries to create meaningful, impactful and lasting learning opportunities. We leverage...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement: Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance: Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies: Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...